Fundamental Analysis of EDGEWISE THERAPEUTICS INC(NASDAQ:EWTX) stock

Fundamental Rating

We assign a fundamental rating of 3 out of 10 to EWTX. EWTX was compared to 194 industry peers in the Pharmaceuticals industry. EWTX has a great financial health rating, but its profitability evaluates not so good. EWTX has a expensive valuation and it also scores bad on growth.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year EWTX has reported negative net income.

EWTX had a negative operating cash flow in the past year.

EWTX had negative earnings in each of the past 5 years.

In the past 5 years EWTX always reported negative operating cash flow.

1.2 Ratios

EWTX's Return On Assets of -24.31% is fine compared to the rest of the industry. EWTX outperforms 60.42% of its industry peers.

With a decent Return On Equity value of -25.42%, EWTX is doing good in the industry, outperforming 68.23% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-24.31%
ROE	-25.42%
ROIC	N/A

ROA(3y)-20.96%

ROA(5y)-23.12%

ROE(3y)-22.18%

ROE(5y)-24.3%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for EWTX so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

EWTX has more shares outstanding than it did 1 year ago.

There is no outstanding debt for EWTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

An Altman-Z score of 80.34 indicates that EWTX is not in any danger for bankruptcy at the moment.

With an excellent Altman-Z score value of 80.34, EWTX belongs to the best of the industry, outperforming 98.96% of the companies in the same industry.

EWTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	80.34

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

EWTX has a Current Ratio of 26.35. This indicates that EWTX is financially healthy and has no problem in meeting its short term obligations.

EWTX has a Current ratio of 26.35. This is amongst the best in the industry. EWTX outperforms 94.79% of its industry peers.

A Quick Ratio of 26.35 indicates that EWTX has no problem at all paying its short term obligations.

EWTX has a better Quick ratio (26.35) than 94.79% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	26.35
Quick Ratio	26.35

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for EWTX have decreased by -5.63% in the last year.

EPS 1Y (TTM)-5.63%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%12.2%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

EWTX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.39% yearly.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y3.99%

EPS Next 2Y-10.04%

EPS Next 3Y-8.08%

EPS Next 5Y12.39%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for EWTX. In the last year negative earnings were reported.

Also next year EWTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A cheap valuation may be justified as EWTX's earnings are expected to decrease with -8.08% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-10.04%

EPS Next 3Y-8.08%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for EWTX!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

EDGEWISE THERAPEUTICS INC

NASDAQ:EWTX (11/22/2024, 8:00:02 PM)

After market: 32.2 0 (0%)

32.2

+0.22 (+0.69%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap3.05B

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-24.31%
ROE	-25.42%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	26.35
Quick Ratio	26.35
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

High Growth Momentum

Growth

EPS 1Y (TTM)-5.63%

EPS 3YN/A

EPS 5Y

EPS Q2Q%

EPS Next Y3.99%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5Y

Sales Q2Q%

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

EDGEWISE THERAPEUTICS INC (EWTX)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens